Could a cancer drug cut surgeries for rare throat growths?
NCT ID NCT05797246
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This study tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce how often people with recurrent respiratory papillomatosis (RRP) need surgery to clear wart-like growths from their airways. About 21 adults who need at least two surgeries per year will receive the drug for about a year. The goal is to see if the time between surgeries can be extended by at least one month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab
What this could lead to
If it works, this could mean fewer surgeries for people with RRP, helping them breathe and speak more easily.
What could go wrong
This is a small, early-phase trial with only 21 participants. The drug may not work for everyone, and side effects like bleeding or high blood pressure are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.